Taisho Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Taisho Pharmaceutical Co., Ltd.
The Quality Lowdown: CMC Challenges Include Pfizer Unit's Quest For Injectable Acetaminophen
Pfizer’s InnoPharma unit finally overcame US FDA’s concerns about injectable acetaminophen GMPs and leachables. Meanwhile, Azurity resolved zonisamide manufacturing issues, Amphastar overcame doubts about naloxone’s nasal spray device, Incyte reused Zynyz CMC data, Cidara showed Rezzayo vials had enough powder, Pharming showed equivalence between Joenja tablets and capsules, and Orphalan avoided half-tablet stability testing of its functionally scored Cuvrior tablets.
In Saudi Arabia, A Vision Of Healthcare Spurs Growth
As the Kingdom of Saudi Arabia reduces its dependence on oil as an export, one sector it is building up is the life sciences industry. The government is encouraging global companies to manufacture and invest domestically and they are improving their regulatory system and working with local players to enhance access to patients.
Hikma Sees Signs Of A Bounceback For Generics
After a tough 2022 that saw Hikma suffer an 18% drop in generics sales – albeit mostly offset by growth in the firm’s injectables and branded divisions – the company has announced fresh forecasts for 2023 that suggest the generics segment will bounce back with growth of a fifth.
Hikma Names Injectables Chief Mishlawi As CEO
Hikma’s president of injectables, Riad Mishlawi, has been chosen to become the firm’s new CEO from the start of September. The move comes after a period of success in injectables for Hikma, at the same time as the firm attempts to revive the fortunes of its generics business.
- Topical Delivery
- Drug Delivery
- Other Names / Subsidiaries
- Hoepharma Holdings Sdn. Bhd.
- Taisho Toyama Pharmaceutical Co., Ltd.
- TOKUHON Corporation
- UPSA SAS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.